InflaRx N.V. Common Stock (IFRX)
Stock · NASDAQ · Health Care
$2.23as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta68.6%
Support level
$0.918438
Industry
Biotechnology: Pharmaceutical Preparations
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the trea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 65
- Website
- www.inflarx.de/
Fundamentals
- 1-day range
- $2.21$2.37
- Market cap
- $126.51M
- P/E (trailing)
- —
- P/E (forward)
- -5.53
- EPS (trailing)
- $-0.47
- Dividend yield
- —
- Beta
- 2.62
- Avg. volume
- 1.18M
52-week range
$0.7984$2.95
Next earnings: November 9, 2026 · EPS estimate $-0.05confirmed
Forecasts
8 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$14.08
+531.3%
Median
$8.54
+282.9%
Low
$3.02
+35.3%
InflaRx N.V. Common Stock Competitors
Chosen by industry and closest market cap.
- IFRXInflaRx N.V. Common Stock$2.22▼ 2.20%Market cap $126.51MP/E —$0.7984$2.95
- PMNProMIS Neurosciences Inc. Common Shares (ON)$13.79▼ 1.43%Market cap $126.80MP/E —$6.27$27.4
- VTVTvTv Therapeutics Inc. Class A Common Stock$32.17▼ 1.92%Market cap $127.58MP/E 55.59$15.79$44
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$2.22▼ 2.63%Market cap $124.04MP/E —$1.23$3.82
- ADCTADC Therapeutics SA Common Shares$1.15▲ 2.68%Market cap $133.55MP/E —$0.7796$4.98
- GNLXGenelux Corporation Common Stock$2.66▼ 7.64%Market cap $133.62MP/E —$2.29$8.54
- SPRBSpruce Biosciences Inc. Common Stock$60.05▼ 5.13%Market cap $118.73MP/E —$7$240
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IFRX InflaRx N.V. Common Stock | $126.51M | — | $2.22 | ▼ 2.20% | $0.7984$2.95 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $126.80M | — | $13.79 | ▼ 1.43% | $6.27$27.4 |
| VTVT vTv Therapeutics Inc. Class A Common Stock | $127.58M | 55.59 | $32.17 | ▼ 1.92% | $15.79$44 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $124.04M | — | $2.22 | ▼ 2.63% | $1.23$3.82 |
| ADCT ADC Therapeutics SA Common Shares | $133.55M | — | $1.15 | ▲ 2.68% | $0.7796$4.98 |
| GNLX Genelux Corporation Common Stock | $133.62M | — | $2.66 | ▼ 7.64% | $2.29$8.54 |
| SPRB Spruce Biosciences Inc. Common Stock | $118.73M | — | $60.05 | ▼ 5.13% | $7$240 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6benzinga · 8/7/2026
- Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6Benzinga · 8/7/2026
- InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss EstimatesChartMill · 8/6/2026
- InflaRx Q2 EPS $(0.10) Misses $(0.08) EstimateBenzinga · 8/6/2026
See the full, filterable feed with live charts on the MarketWall dashboard.